Low-dose Atropine for the Prevention of Myopia Progression in Danish Children
Key facts
- Who runs it
- Line Kessel
- Where
- Denmark3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 97 people enrolled
- Started
- 30 May 2019
- Ended
- 23 Apr 2024
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- 0.1% atropine and 0.01% atropine
- 0.01% atropine
- 0.9% Sodium-chloride
- Record updated
- 29 June 2025
Who can take part
- Age
- 6 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Children aged ≥6-<9 years: myopia ≤-1 (spherical power) in at least one eye
- Children aged ≥9-≤12 years: myopia ≤-2 (spherical power) in at least one eye
- Cylinder less than 1.5 diopters
Who cannot take part
- Previous eye surgery
- Previous use of agents thought to affect myopia progression, e.g. atropine, pirenzepine or 7-methylxanthine (metabolite of caffeine and theobromine) and orthokeratology contact lenses
- Collagen syndroms (Ehlers-Danlos syndrome, Marfan syndrome and Stickler syndrome)
- Known allergy to atropine or any of the contents of the trial medication (active and in-active ingredients) used in the study
- Serious systemic health troubles (e.g., cardiac or respiratory illness) and developmental disorders and delays
- Myopia related to retinal dystrophies
- Other ocular pathology (e.g., amblyopia, strabismus)
- Non-compliance to eye examinations
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Myopia (nearsightedness) is increasing in prevalence throughout the world. It is associated with a risk of potentially blinding complications such as retinal detachment and myopic maculopathy. There is a direct association between the degree of myopia and the risk of complications. Myopia develops in childhood and during adolescence. To prevent higher degrees of myopia, we need to halt disease progression in children and teenagers. Low-dose atropine eye drops have been shown to reduce myopia progression by 50% in Asian populations but its effect in non-Asian populations is unknown. The aim of this study is to investigate if low-dose atropine can reduce myopia progression in Danish children and teenagers. The study is an investigator initiated randomized clinical trial conducted as a collaboration between three Danish Eye Departments covering all of Denmark.
The 3 groups in the trial
- Loading doseTreatment being tested
In phase 1 (treatment phase), the participants (n=33) will receive 0.1% atropine loading dose for 6 months followed by 0.01 % atropine for 18 months. The eye drops are administered as one eye drop daily in each eye at bedtime. In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months.
Treatment: 0.1% atropine and 0.01% atropine
- Low doseTreatment being tested
In phase 1 (treatment phase), the participants (n=32) will receive 0.01 % atropine for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime. In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months.
Treatment: 0.01% atropine
- PlaceboPlacebo, for comparison
In phase 1 (treatment phase), the participants (n=32) will receive placebo eye drops for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime. In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months.
Treatment: 0.9% Sodium-chloride
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Low-dose Atropine for the Prevention of Myopia Progression in Danish Children - a Randomized, Double-masked, Multicenter, 36-month Prospective 1:1:1 Study of Safety and Efficacy of 0.1% Atropine Loading Dose to Single 0.01% Atropine and Placebo
- Publications
- Peripapillary hyperreflective ovoid mass-like structure (PHOMS): prevalence, risk factors, and development over time in Danish myopic children.Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2024
- The Macular Choroidal Thickness in Danish Children with Myopia After Two-Year Low-Dose Atropine and One-Year Wash-Out: A Placebo-Controlled, Randomized Clinical Trial.Ophthalmology and therapy, 2024
- Record updated
- 29 June 2025